PLCD1 has been shown to function as a TSG by inhibiting WNT/β-catenin in ESCC, BrCa and CRC [14, 30, 31], consistent with our findings that PLCD1 inhibits active-β-catenin and downstream target gene transcription, including MMP7, c-Myc and CCND1, hence suppressing proliferation, migration and invasion of RCC cells. The gene discussed is PLCD1; the disease is invasive breast carcinoma.